Hopefully the purchase agreements get improved moving forward. Having said that, remember we are trying to change all this via the S-1 and funding. Having an investor "partnering" with us is way different than CM and Veneto. All we had to use at the time were shares. There is only so much restricting that can be done.

Non dilutive financing from big pharma is the answer as we get trials moving along. Plus our own revenue.

We can be mad at CM but the Veneto fiasco is a triple whammy or maybe worse. Didn't give us all the assets, non compliant program lead to little/no revenue, we overpaid and they sold shares. Lots of bad there.

In the case of CM, had the Veneto deal as expected and GNBT not screwed up the timing of the Generex up listing and NGIO spin off/listing, we LIKELY would have had the money to pay them off before they sold.